CoChat

ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

mutation as a combination biomarker in predicting response to ICT in CheckMate275 and IMvigor210. Combination of the two biomarkers in baseline tumor tissues suggested improved OS compared to either single biomarker. Cumulatively, this study revealed that the combination of CXCL13 plus ARID1A may improve prediction capability for patients receiving ICT.

Overview

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.abc4220

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 37 references

Cited by

Metadata

Authors
Goswami, S., Chen, Y., Anandhan, S., Szabo, P. M., Basu, S., Blando, J. M., Liu, W., Zhang, J., Natarajan, S. M., Xiong, L., Guan, B., Yadav, S. S., Saci, A., Allison, J. P., Galsky, M. D., & Sharma, P.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Department of Translational Medicine, Bristol Myers Squibb, Princeton, NJ 08540, USA.
  • Bristol-Myers Squibb (United States) (US)
  • Tisch Cancer Institute (US)
Corresponding author
Sharma, Padmanee
Venue
Science Translational Medicine
Published
2020-06-17
Volume
12
Issue
548
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
OpenAlex
W3036281565
Cited by
133
References
36
Citations by year
2026: 10 · 2025: 18 · 2024: 21 · 2023: 24 · 2022: 26 · 2021: 29 · 2020: 5
FWCI
7.58
Type
journal article
Language
en
Open access
closed
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
Parker Institute for Cancer Immunotherapy
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords
ARID1A mutation, immune checkpoint inhibitors, biomarkers, metastatic urothelial carcinoma, treatment response prediction, overall survival, IMvigor210
MeSH terms
Animals, Urinary Bladder Neoplasms, DNA-Binding Proteins, Humans, Mutation, Transcription Factors, Biomarkers, Tumor, Biomarkers, Mice, Chemokine CXCL13, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.